TrialAdvances in therapy2018

72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.

Hirofumi Ochi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.